logo
  

AT&T Continues To See Healthy Consumer Demand

Telecom giant AT&T Inc. (T) said it continues to grow customer relationships in its strategic focus areas of 5G and fiber. It continues to see healthy consumer demand even with continued expectations that 2022 postpaid wireless industry demand is unlikely to replicate 2021 levels.

At the Bank of America C-Suite TMT Conference, Jeff McElfresh, chief operating officer of AT&T, said it remains comfortable that the company can deliver improving postpaid phone ARPU trends in 2022. He reiterated prior commentary from the company that postpaid phone ARPU could edge up sequentially in the second quarter.

As noted previously, the company continues to anticipate gradual improvement in year-over-year mobility EBITDA trends throughout 2022. The company expects a more pronounced impact from the previously announced 3G network shutdown and the absence of approximately $100 million in CAF II and FirstNet related reimbursements in the second quarter. However, the revenue and EBITDA impacts of the items are expected to be more than mitigated in the second half of year by organic service revenue growth and the lapping of 3G shutdown costs in the second half of 2021.

AT&T's fiber build continues to progress with expectations to achieve 30+ million total customer locations by 2025.

As previously noted, the company has yet to see a recovery in government sector demand trends, which impacted the business during the first quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency. Philip Morris International Inc. (PM) reported Tuesday that net earnings attributable to PMI for the quarter grew to $2.15 billion or $1.38 per share from $2.00 billion or $1.28 per share in the prior-year quarter. Excluded items, adjusted earnings for the quarter were $1.50 per share, compared to... Novartis AG's shares were gaining more than 4 percent in Switzerland and more than 5 percent in pre-market activity on the NYSE after the Swiss drug major reported Tuesday higher first-quarter profit, above market estimates, with strong sales growth. The company also raised its fiscal 2024 outlook for growth in sales and core operating income.

First quarter growth data from China gained the maximum focus this week as trends in the massive emerging economy impact its trading partners. Elsewhere, the IMF released its latest global macroeconomic projections. Read our story to find out why comments from the Fed Chair Powell damped rate cut expectations. Meanwhile, there was some survey data that kindled hopes of a recovery in manufacturing. In the U.K., inflation data for March revealed some confusing trends.

View More Videos
Follow RTT